<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001221</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11068</org_study_id>
    <nct_id>NCT01001221</nct_id>
  </id_info>
  <brief_title>Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor</brief_title>
  <official_title>A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel With Gemcitabine to Determine The Safety, And Pharmacokinetics In Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        -  Study part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting
           Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with
           gemcitabine, every 3 weeks in patients with advanced solid malignancies.

        -  Study part 2: To determine the antitumor activity of cabazitaxel in combination with
           gemcitabine, in an additional extended cohort of 15 patients with advanced solid
           malignancies treated with the defined MTD, as assessed by objective response rate (ORR)
           according to the revised guideline for Response Evaluation Criteria in Solid Tumours
           (RECIST 1.1 criteria).

      Secondary Objectives:

        -  To assess the safety profile of the combination regimen of cabazitaxel with gemcitabine.

        -  To assess the pharmacokinetics (PK) of cabazitaxel, gemcitabine and its metabolite 2',2'
           difluorodeoxyuridine (dFdU) when given in combination.

        -  To determine Time to Progression (TTP), Objective Response Rate (ORR), and Duration of
           Response (DR), in the extended cohort of patients treated at the MTD in Part 2 of the
           study and the patients who received the MTD in Part 1 component.

      For study part 1, dose levels were to be escalated according to predefined dose escalation
      decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at
      least 2 patients developed a DLT during the first 3 weeks of treatment. There was no further
      dose escalation when this dose was achieved. The MTD was defined as the highest dose at which
      0 or 1 of 3 to 6 patients, respectively, experienced DLT during the first 3 weeks of
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of a screening phase (maximum length of 21-day), a treatment phase with
      21-day treatment cycles and a 30-day follow-up visit after the last dose of study medication.

      The cut-off date for study part 1 was when last participant completed the first treatment
      cycle and the subsequent 30 days follow-up.

      The cut off date for study part 2 was when all participants experienced disease progression,
      unacceptable toxicity, consent withdrawal or the last participant had completed 26 weeks or 6
      cycles on study treatment, whichever came first.

      Participants could continue to be treated on study as long as they were benefiting from study
      treatment and had not met study withdrawal criteria. After withdrawal from study treatment,
      further treatment, if any, was at the discretion of the Investigator.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Maximum tolerated dose not able to be determined
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Dose Limiting Toxicities During Dose Escalation</measure>
    <time_frame>Day 1 to Day 21 of the first treatment cycle</time_frame>
    <description>Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate With MTD</measure>
    <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
    <description>Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator.
CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to &lt;10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion.
The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Progression With MTD</measure>
    <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
    <description>Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (&gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of &gt;=1 new lesion and/or unequivocal progression of existing non-target lesions).
Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response With MTD</measure>
    <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
    <description>Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death.
Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events</measure>
    <time_frame>from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)</time_frame>
    <description>Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE.
Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased.
NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
    <description>Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL.
Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
    <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</measure>
    <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
    <description>Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion;
Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
    <description>Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion;
Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
    <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</measure>
    <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
    <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</measure>
    <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC</measure>
    <time_frame>Day 1 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion) and Day 8 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion)</time_frame>
    <description>Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Neoplasms, Malignant</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.
On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion
Route of administration: Intravenous infusion over 60 minutes
Dosage:
Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1</description>
    <arm_group_label>Cabazitaxel + gemcitabine</arm_group_label>
    <other_name>XRP6258</other_name>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Pharmaceutical form: According to United States Package Insert (USPI)
Route of administration: Intravenous infusion over 30 minutes
Dosage:
Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1.</description>
    <arm_group_label>Cabazitaxel + gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically or cytologically confirmed advanced solid malignancy that is metastatic
             or unresectable, and for which standard curative measures do not exist.

        Exclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; or =2

          -  Anticipation of need for a major surgical procedure or radiation therapy during the
             study treatment

          -  Absence of completion of all prior chemotherapy, biological therapy, targeted
             non-cytotoxic therapy &gt; or = 3 weeks; and radiotherapy &gt; or = 4 weeks prior to
             registration. For part 2 only, prior treatment with radiotherapy, chemoembolization
             therapy, or cryotherapy is allowed if these therapies are not directed to the areas of
             measurable disease being used for the purposes of this protocol. (4 weeks of washout
             period is required prior to start the treatment in Part 2)

          -  Concurrent treatment in another clinical trial or with any other cancer therapy or
             patients planning to receive these treatments during the study

          -  Other concurrent serious illness or medical condition, including active infection or
             human immunodeficiency virus (HIV) disease

          -  History of any other malignancy with the exception of adequately treated basal cell or
             squamous cell skin cancer, or in situ carcinoma of the cervix uteri

          -  Patients without resolution of all clinically significant toxic effects (excluding
             alopecia) of any prior therapy to grade &lt; or = 1 by National Cancer Institute's Common
             Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0 or to within the
             limits listed in the specific inclusion/exclusion criteria

          -  Other severe acute or chronic medical or psychiatric condition, or significant
             laboratory abnormality requiring further investigation that may cause undue risk for
             the patient's safety, inhibit protocol participation, or interfere with interpretation
             of study results, and in the judgment of the investigator would make the patient
             inappropriate for entry into this study

          -  Symptomatic brain metastases or leptomeningeal disease. Patients with asymptomatic or
             stable brain metastases are allowed

          -  Women of childbearing potential not protected by highly effective contraceptive method
             of birth control. All patients of childbearing potential that do not have a negative
             pregnancy test within the 7 days prior to registration

          -  Patients who are pregnant or breastfeeding

          -  For part 2, absence of measurable disease as defined by the most current version of
             the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. For the Part 1
             component, patients with non-measurable disease are accepted

          -  Inadequate bone marrow or liver or renal organ function

          -  Any condition which is considered a contraindication to gemcitabine in the local
             labelling

          -  Prior treatment with cabazitaxel within the last 2 years

          -  History of severe hypersensitivity grade 3 or 4 to taxanes, Polysorbate-80, or to
             compounds with similar chemical structures

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <results_first_submitted>May 20, 2013</results_first_submitted>
  <results_first_submitted_qc>September 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2013</results_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in 4 sites in the United States. Since it was not possible to determine the maximum Tolerated Dose (MTD) in study part 1, no participant was enrolled in study part 2 and the study was stopped.</recruitment_details>
      <pre_assignment_details>At each dose level, there was a 1-week gap between the treatment of the first participant and the next 2 participants to evaluate toxicity.
Before escalating to the next dose level, at least 3 participants were to be evaluable for the criteria defining dose limiting toxicity (DLT).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level 0</title>
          <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level -1</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level -2</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Gemcitabine + Cabazitaxel Dose Level 0</title>
          <description>gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="P5">
          <title>Part 2: Cabazitaxel + Gemcitabine MTD</title>
          <description>Cabazitaxel IV and gemcitabine IV on Day 1 then, gemcitabine IV on Day 8 at the Maximum Tolerated Dose (MTD) as determined in study part 1
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0">Inability to determine the MTD during study part 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Treatment Cycle</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants treated until disease progression or unacceptable toxicity.</participants>
                <participants group_id="P2" count="0">Participants treated until disease progression or unacceptable toxicity.</participants>
                <participants group_id="P3" count="0">Participants treated until disease progression or unacceptable toxicity.</participants>
                <participants group_id="P4" count="0">Participants treated until disease progression or unacceptable toxicity.</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated; protocol exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level 0</title>
          <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level -1</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Cabazitaxel + Gemcitabine Dose Level -2</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Gemcitabine + Cabazitaxel Dose Level 0</title>
          <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="6.6"/>
                    <measurement group_id="B2" value="59.2" spread="9.2"/>
                    <measurement group_id="B3" value="53.0" spread="14.8"/>
                    <measurement group_id="B4" value="56.3" spread="16.1"/>
                    <measurement group_id="B5" value="57.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.87" spread="0.32"/>
                    <measurement group_id="B2" value="1.82" spread="0.21"/>
                    <measurement group_id="B3" value="1.98" spread="0.42"/>
                    <measurement group_id="B4" value="1.84" spread="0.12"/>
                    <measurement group_id="B5" value="1.87" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG criteria:
0: Fully active
1: Ambulatory, carry out work of a light or sedentary nature
2: Ambulatory, capable of all selfcare
3: Capable of limited selfcare, confined to bed or chair more than 50% of waking hours
4: Completely disabled, no selfcare, totally confined to bed or chair
5: Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle/soft tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovaries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histological Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at Diagnosis</title>
          <description>Cancer staging is on a scale of I-IV with higher numbers indicating an increase in progression of the disease.
Stage I: cancers are localized to one part of the body. Stage II: cancers are early locally advanced. Stage III: cancers are late locally advanced. Stage IV: cancers have often metastasized, or spread to other organs or throughout the body.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Organs Involved</title>
          <units>organs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="1.6"/>
                    <measurement group_id="B2" value="2.6" spread="0.5"/>
                    <measurement group_id="B3" value="3.3" spread="0.6"/>
                    <measurement group_id="B4" value="2.0" spread="0.6"/>
                    <measurement group_id="B5" value="2.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Dose Limiting Toxicities During Dose Escalation</title>
        <description>Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).</description>
        <time_frame>Day 1 to Day 21 of the first treatment cycle</time_frame>
        <population>DLT population: All participants who completed assessments for DLT evaluation for Cycle 1 and either:
received study treatment during Cycle 1 and had DLT or
did not have DLT and received a full dose of study treatment (no delay/reduction) during Cycle 1 and did not receive hematopoietic growth factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Dose Limiting Toxicities During Dose Escalation</title>
          <description>Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).</description>
          <population>DLT population: All participants who completed assessments for DLT evaluation for Cycle 1 and either:
received study treatment during Cycle 1 and had DLT or
did not have DLT and received a full dose of study treatment (no delay/reduction) during Cycle 1 and did not receive hematopoietic growth factors.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Progression With MTD</title>
        <description>Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (&gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of &gt;=1 new lesion and/or unequivocal progression of existing non-target lesions).
Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
        <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine MTD</title>
            <description>Cabazitaxel IV and gemcitabine IV on Day 1 then, gemcitabine IV on Day 8 at the maximum tolerated dose as determined in study part 1
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Progression With MTD</title>
          <description>Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (&gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of &gt;=1 new lesion and/or unequivocal progression of existing non-target lesions).
Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response With MTD</title>
        <description>Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death.
Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
        <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine MTD</title>
            <description>Cabazitaxel IV and gemcitabine IV on Day 1 then, gemcitabine IV on Day 8 at the maximum tolerated dose as determined in study part 1
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response With MTD</title>
          <description>Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death.
Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events</title>
        <description>Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE.
Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased.
NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.</description>
        <time_frame>from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)</time_frame>
        <population>all treated (AT) population: All enrolled participants who received at least 1 part of a dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adverse Events</title>
          <description>Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE.
Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased.
NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.</description>
          <population>all treated (AT) population: All enrolled participants who received at least 1 part of a dose of study treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Grade 3-4 drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Drug-related serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to drug withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Drug-related AE leading to drug withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Participant Best Response as Per the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
        <description>Participant Best response was assessed by investigator using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1:
Complete response (CR): Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to &lt;10 mm:
Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion;
Progressive disease (PD): &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of &gt;=1 new lesion and/or unequivocal progression of existing non-target lesions;
Stable disease (SD): not a CR, PR or PD.</description>
        <time_frame>Up to a maximum of 22 cycles (median 4 cycles)</time_frame>
        <population>all treated (AT) population: All enrolled participants who received at least 1 part of a dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Best Response as Per the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
          <description>Participant Best response was assessed by investigator using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1:
Complete response (CR): Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to &lt;10 mm:
Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion;
Progressive disease (PD): &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of &gt;=1 new lesion and/or unequivocal progression of existing non-target lesions;
Stable disease (SD): not a CR, PR or PD.</description>
          <population>all treated (AT) population: All enrolled participants who received at least 1 part of a dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)</title>
        <description>Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL.
Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population: All enrolled participants who received at least 1 part of a dose of study treatment and had at least 1 post treatment analyzable PK sample, and with no prohibited concomitant medications</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)</title>
          <description>Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL.
Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
          <population>PK population: All enrolled participants who received at least 1 part of a dose of study treatment and had at least 1 post treatment analyzable PK sample, and with no prohibited concomitant medications</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="43.7"/>
                    <measurement group_id="O2" value="150" spread="80.9"/>
                    <measurement group_id="O3" value="273" spread="21.9"/>
                    <measurement group_id="O4" value="118" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)</title>
          <population>PK population as previously defined</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.92" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.87" upper_limit="0.95"/>
                    <measurement group_id="O3" value="0.94" lower_limit="0.88" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.93" lower_limit="0.92" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
        <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.</description>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
          <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.</description>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556" spread="500"/>
                    <measurement group_id="O2" value="352" spread="101"/>
                    <measurement group_id="O3" value="344" spread="114"/>
                    <measurement group_id="O4" value="315" spread="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)</title>
        <description>Area under the plasma concentration versus time curve extrapolated to infinity</description>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined. Six participants' assays could not be used for AUC.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)</title>
          <description>Area under the plasma concentration versus time curve extrapolated to infinity</description>
          <population>PK population as previously defined. Six participants' assays could not be used for AUC.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876" spread="730"/>
                    <measurement group_id="O2" value="420" spread="77.3"/>
                    <measurement group_id="O3" value="462" spread="156"/>
                    <measurement group_id="O4" value="306" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)</title>
          <population>PK population as previously defined</population>
          <units>hours (hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" spread="40.3"/>
                    <measurement group_id="O2" value="88.3" spread="35.1"/>
                    <measurement group_id="O3" value="75.6" spread="27.8"/>
                    <measurement group_id="O4" value="70.3" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined. Six participants' assays could not be used for CL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)</title>
          <population>PK population as previously defined. Six participants' assays could not be used for CL.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="38.4"/>
                    <measurement group_id="O2" value="64.3" spread="16.2"/>
                    <measurement group_id="O3" value="59.5" spread="6.38"/>
                    <measurement group_id="O4" value="90.8" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined. One participant's assay could not be used for Vss.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)</title>
          <population>PK population as previously defined. One participant's assay could not be used for Vss.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6780" spread="3250"/>
                    <measurement group_id="O2" value="4980" spread="818"/>
                    <measurement group_id="O3" value="3930" spread="1170"/>
                    <measurement group_id="O4" value="5570" spread="2100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined. Six participants' assays could not be used for CL/BSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
          <population>PK population as previously defined. Six participants' assays could not be used for CL/BSA.</population>
          <units>L/hr/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="18.3"/>
                    <measurement group_id="O2" value="36.1" spread="6.58"/>
                    <measurement group_id="O3" value="31.9" spread="12.6"/>
                    <measurement group_id="O4" value="49.6" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
        <time_frame>before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion</time_frame>
        <population>PK population as previously defined. One participant's assays could not be used for Vss/BSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
          <population>PK population as previously defined. One participant's assays could not be used for Vss/BSA.</population>
          <units>L/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3530" spread="1650"/>
                    <measurement group_id="O2" value="2690" spread="434"/>
                    <measurement group_id="O3" value="1980" spread="8.83"/>
                    <measurement group_id="O4" value="3020" spread="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</title>
        <description>Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion;
Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</title>
          <description>Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion;
Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
          <population>PK population as previously defined.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14600" spread="6050"/>
                    <measurement group_id="O2" value="35600" spread="27200"/>
                    <measurement group_id="O3" value="11400" spread="3270"/>
                    <measurement group_id="O4" value="19000" spread="9130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</title>
          <population>PK population as previously defined</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.47" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.37" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.60" lower_limit="0.53" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.42" lower_limit="0.37" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7320" spread="1650"/>
                    <measurement group_id="O2" value="16000" spread="11100"/>
                    <measurement group_id="O3" value="6120" spread="3350"/>
                    <measurement group_id="O4" value="9920" spread="5290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6290" spread="1440"/>
                    <measurement group_id="O2" value="21900" spread="10800"/>
                    <measurement group_id="O3" value="8530">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="9970" spread="5310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.295" spread="0.118"/>
                    <measurement group_id="O2" value="0.254" spread="0.0570"/>
                    <measurement group_id="O3" value="0.202">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="0.256" spread="0.0933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313" spread="120"/>
                    <measurement group_id="O2" value="85.1" spread="40.6"/>
                    <measurement group_id="O3" value="123">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="174" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="86.2"/>
                    <measurement group_id="O2" value="28.9" spread="30.4"/>
                    <measurement group_id="O3" value="47.0">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="51.6" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>L/hr/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="31.3"/>
                    <measurement group_id="O2" value="49.8" spread="27.0"/>
                    <measurement group_id="O3" value="78.4">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="96.4" spread="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
          <population>PK population as previously defined. Five participants' assays could not be used in the analysis.</population>
          <units>L/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="31.7"/>
                    <measurement group_id="O2" value="17.3" spread="18.9"/>
                    <measurement group_id="O3" value="29.9">Single participant in analysis</measurement>
                    <measurement group_id="O4" value="28.7" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</title>
        <description>Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion;
Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</title>
          <description>Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints:
Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion;
Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion;
Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
          <population>PK population as previously defined</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10200" spread="283"/>
                    <measurement group_id="O2" value="34500" spread="30800"/>
                    <measurement group_id="O4" value="14100" spread="12200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</title>
          <population>PK population as previously defined</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.52" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.42" upper_limit="0.55"/>
                    <measurement group_id="O4" value="0.47" lower_limit="0.40" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5530" spread="1150"/>
                    <measurement group_id="O2" value="15300" spread="11900"/>
                    <measurement group_id="O4" value="7710" spread="6840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>hours (hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.222">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="0.282" spread="0.0218"/>
                    <measurement group_id="O4" value="0.317" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6360">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="18500" spread="12300"/>
                    <measurement group_id="O4" value="7780" spread="6880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="110" spread="55.8"/>
                    <measurement group_id="O4" value="252" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="36.2" spread="19.4"/>
                    <measurement group_id="O4" value="93.3" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>L/hr/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="62.8" spread="32.7"/>
                    <measurement group_id="O4" value="143" spread="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>L/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="20.6" spread="11.6"/>
                    <measurement group_id="O4" value="52.3" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</title>
        <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)</title>
          <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
          <population>PK population as previously defined</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32200" spread="10000"/>
                    <measurement group_id="O2" value="32500" spread="10800"/>
                    <measurement group_id="O3" value="25500" spread="8770"/>
                    <measurement group_id="O4" value="21100" spread="5980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)</title>
          <population>PK population as previously defined</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.50" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.47" upper_limit="0.83"/>
                    <measurement group_id="O3" value="0.65" lower_limit="0.53" upper_limit="0.77"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.50" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227000" spread="27500"/>
                    <measurement group_id="O2" value="235000" spread="47400"/>
                    <measurement group_id="O3" value="167000" spread="47500"/>
                    <measurement group_id="O4" value="168000" spread="57000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)</title>
          <population>PK population as previously defined</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" spread="2.22"/>
                    <measurement group_id="O2" value="9.41" spread="0.837"/>
                    <measurement group_id="O3" value="7.96" spread="1.87"/>
                    <measurement group_id="O4" value="12.1" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</title>
        <time_frame>7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)</title>
          <population>PK population as previously defined. Two participants' assays could not be used in the analysis.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273000" spread="58100"/>
                    <measurement group_id="O2" value="285000" spread="61200"/>
                    <measurement group_id="O3" value="191000" spread="66900"/>
                    <measurement group_id="O4" value="151000" spread="37700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</title>
        <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>All enrolled participants who received at least 1 part of a dose of study treatment and had at least 1 post treatment analyzable PK sample and with no prohibited concomitant medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)</title>
          <description>Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU).
2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL.
PK parameters were calculated from plasma concentrations using non-compartmental analysis.</description>
          <population>All enrolled participants who received at least 1 part of a dose of study treatment and had at least 1 post treatment analyzable PK sample and with no prohibited concomitant medications.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27400" spread="3180"/>
                    <measurement group_id="O2" value="34800" spread="8630"/>
                    <measurement group_id="O4" value="18700" spread="4740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)</title>
          <population>PK population as previously defined</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.52" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.55" upper_limit="1.02"/>
                    <measurement group_id="O4" value="0.72" lower_limit="0.70" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)</title>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216000" spread="3700"/>
                    <measurement group_id="O2" value="287000" spread="77500"/>
                    <measurement group_id="O4" value="141000" spread="26400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)</title>
          <population>PK population as previously defined</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" spread="1.11"/>
                    <measurement group_id="O2" value="8.55" spread="0.820"/>
                    <measurement group_id="O4" value="9.10" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</title>
        <time_frame>7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1</time_frame>
        <population>PK population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)</title>
          <population>PK population as previously defined</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240000" spread="11300"/>
                    <measurement group_id="O2" value="340000" spread="100000"/>
                    <measurement group_id="O4" value="168000" spread="27600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC</title>
        <description>Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.</description>
        <time_frame>Day 1 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion) and Day 8 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion)</time_frame>
        <population>Enrolled participants who received at least 1 part of a dose of study treatment and had valid Day 1 and Day 8 PK samples. Valid PK samples included at least 1 post treatment analyzable PK sample and no prohibited concomitant medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
            <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
            <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
          <group group_id="O4">
            <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
            <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC</title>
          <description>Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.</description>
          <population>Enrolled participants who received at least 1 part of a dose of study treatment and had valid Day 1 and Day 8 PK samples. Valid PK samples included at least 1 post treatment analyzable PK sample and no prohibited concomitant medications.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="1.17" lower_limit="0.661" upper_limit="2.49"/>
                    <measurement group_id="O4" value="1.11" lower_limit="0.994" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15">Single participant in analysis</measurement>
                    <measurement group_id="O2" value="1.24" lower_limit="0.660" upper_limit="2.47"/>
                    <measurement group_id="O4" value="1.11" lower_limit="0.994" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate With MTD</title>
        <description>Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator.
CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to &lt;10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion.
The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
        <time_frame>Fron Day 1 up to a maximum of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel + Gemcitabine MTD</title>
            <description>Cabazitaxel IV and gemcitabine IV on Day 1 then, gemcitabine IV on Day 8 at the maximum tolerated dose as determined in study part 1
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate With MTD</title>
          <description>Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator.
CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to &lt;10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion.
The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cabazitaxel + Gemcitabine Dose Level 0</title>
          <description>Cabazitaxel 20 mg/m^2 IV followed by gemcitabine 1000 mg/m^2 IV on Day 1 then, gemcitabine 1000 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="E2">
          <title>Cabazitaxel + Gemcitabine Dose Level -1</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 900 mg/m^2 IV on Day 1 then, gemcitabine 900 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="E3">
          <title>Cabazitaxel + Gemcitabine Dose Level -2</title>
          <description>Cabazitaxel 15 mg/m^2 IV followed by gemcitabine 700 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
        <group group_id="E4">
          <title>Gemcitabine + Cabazitaxel Dose Level 0</title>
          <description>Gemcitabine 700 mg/m^2 IV followed by cabazitaxel 15 mg/m^2 IV on Day 1 then, gemcitabine 700 mg/m^2 IV on Day 8
21-day treatment cycles until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood electrolytes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Generalized oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkalne phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 45 days in advance of proposed submission, the Investigator should forward a copy of the manuscript or abstract for review by the sponsor, and, if necessary, delay publication or communication for a limited time in order to protect the confidentiality or proprietary nature of any information contained therein.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pharmacokinetic results need to be confirmed due to the limited data available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

